ENTA/Ribavarin. Interestingly, Turquoise II and Sapphire I & II involving cirrhotic patients were + Ribavarin only (i.e. no arm sans Ribavarin), and their SVRs fell into the same range as the + Ribavin arms of Pearl II-IV.
From this it's possible to infer that even the cirrhotic patients in Turquoise and Sapphire would have derived no benefit from Ribavarin whatsoever had there been a sans Ribavarin arm. My guess is that this result took the study designers completely by surprise.
Market Data 
Markets 
AI
